---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-007471"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T16:00:22.431668+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports Roche termination of HB-700 deal, 30% workforce cut, $117.5M cash

## Summary
- Roche terminates collaboration for HB-700 (KRAS-mutated cancers) effective April 25, 2024; HOOKIPA regains full rights and remains eligible for IND milestone payment.
- Workforce reduction of ~30% (55 employees) approved; expected severance costs ~$1.5M, non-cash impairment of GMP facility $10M-$13M.
- Company to prioritize HB-200 (HPV16+ HNSCC) and Gilead-partnered infectious disease programs; pauses HB-300 and most preclinical research.
- Preliminary cash and equivalents of $117.5M as of Dec 31, 2023 (unaudited); company expects to conserve resources.

## SEC filing metadata
- accession: 0001104659-24-007471
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.02, 7.01, 2.05, 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/0001104659-24-007471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/tm244291d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-007471
- JSON: https://secwatch.observer/filing/0001104659-24-007471.json
- Plain text: https://secwatch.observer/filing/0001104659-24-007471.txt

## Key facts
- Material Agreements
  HOOKIPA Pharma Inc. terminated Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (effective 2024-01-25).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.
  - Effective: 2024-01-25
  source text: On January 25, 2024, HOOKIPA Pharma Inc. (“HOOKIPA”) received written notice (the “Notice”) from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively referred to as “Roche”) of their decision to terminate the Research Collaboration and License Agreement (the “Collaboration Agreement”) among Roche and Hookipa Biotech GmbH (“HOOKIPA GmbH,” and together with HOOKIPA, the “Company”), a wholly-owned subsidiary of HOOKIPA, dated October 18, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/0001104659-24-007471-index.htm
- Restructurings & Charges
  HOOKIPA Pharma Inc. announced a restructuring with charges of approximately $1.5 million in severance, restructuring and related costs affecting the Company (55 full-time employees, or approximately 30% of the Company's then-current employee base).
  - Type: restructuring
  - Charge: approximately $1.5 million in severance, restructuring and related costs
  - Affected area: the Company
  - Headcount: 55 full-time employees, or approximately 30% of the Company's then-current employee base
  source text: into an effective separation agreement, which includes a general release of claims against the Company. The workforce reduction is expected to result in approximately $1.5 million in severance, restructuring and related costs. HOOKIPA expects a non-cash impairment of “assets under construction” between $10 million and $13 million from the discontinuation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/0001104659-24-007471-index.htm
- Restructurings & Charges
  HOOKIPA Pharma Inc. announced a impairment with charges of between $10 million and $13 million affecting GMP facility project.
  - Type: impairment
  - Charge: between $10 million and $13 million
  - Affected area: GMP facility project
  source text: HOOKIPA expects a non-cash impairment of “assets under construction” between $10 million and $13 million from the discontinuation of the GMP facility project as part of the Reduction Plan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/0001104659-24-007471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.